BPC-157 + TB-500 blend
Also called "Wolverine stack"
A popular pairing in injury-recovery discussions. Most of the supporting work involves each compound separately in cells or animals; there is no controlled human trial of the blend.
Overview
What it is
BPC-157 is an experimental peptide studied in tissue-injury models. TB-500 is a commercial name tied to thymosin beta-4-related material, often a fragment (LKKTETQ) rather than the full protein. A premixed vial and two separate vials are different products.
How it works
BPC-157 increased growth-hormone receptor expression in cultured tendon cells. Thymosin beta-4 improved wound closure in rats. These explain the interest but do not show a combined benefit.
What the research shows
A 2021 retrospective report of 16 knee-pain patients (12 on BPC-157 alone, 4 with thymosin beta-4) found most reported improvement, but there was no control group or standardized function test. No evidence shows the pair beats either ingredient, rehabilitation or standard care.
Studied for
- Tendon cell behaviorlab
- Skin wound healingrats
- Knee painsmall uncontrolled report
Safety and regulatory status
Safety and side effects
The FDA flags limited human safety data and possible immune or impurity-related risks for BPC-157 and the TB-500 fragment. Purity, sterility and endotoxin testing each answer different questions; a purity percentage is not clinical safety evidence.
Regulatory status
Not FDA approved. Both are on FDA's list of bulk substances that may present significant safety risks.
Mixing and dosing reference
Reference information only. Read before using this section.
BPC-157 + TB-500 (10 mg Blend) Dosage Protocol
- Vial
- 10 mg total blend 5 mg BPC-157 + 5 mg TB-500
- Add diluent
- 3 mL
- Concentration
- 3.33 mg/mL
- 1 unit (U-100)
- 33.33 mcg total in 0.01 mL
- Route
- Subcutaneous
Standard / Gradual Approach
| Week | Daily Dose (Total Blend) | Each Peptide | U-100 Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | ~250 mcg each | 15 units (0.15 mL) |
| Weeks 3–4 | 666 mcg (0.67 mg) | ~333 mcg each | 20 units (0.20 mL) |
| Weeks 5–8 | 1,000 mcg (1.0 mg) | ~500 mcg each | 30 units (0.30 mL) |
Advanced / Loading Phase (Optional)
| Phase | Daily Dose (Total Blend) | Each Peptide | U-100 Units (mL) |
|---|---|---|---|
| Loading (Weeks 1–4) | 1,500 mcg (1.5 mg) | ~750 mcg each | 45 units (0.45 mL) |
| Maintenance (Weeks 5–8) | 1,000 mcg (1.0 mg) | ~500 mcg each | 30 units (0.30 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject the diluent slowly down the inside wall of the vial.
- Gently swirl until dissolved. Do not shake.
- Label with the compound, concentration, and preparation date; refrigerate at 2–8 °C (36–46 °F) and protect from light.
Protocol source: PeptideDosages.com
Common questions
What does "synergy" mean here?
A combined effect larger than the separate effects would predict. That has not been demonstrated for this pair.
How long does it take to work?
No dependable timeline has been established.
Does it affect testosterone or the liver?
The available evidence does not answer this reliably.
Related in Performance and Recovery
Sources and further reading (5)
- FDA. Bulk drug substances that may present significant safety risks.
- BPC-157 and growth-hormone receptor expression in tendon fibroblasts, 2014.
- Malinda KM, et al. Thymosin beta-4 in an experimental wound-healing model, 1999.
- Lee E, Padgett B. Intra-articular BPC-157, alone or with thymosin beta-4, for knee pain, 2021.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: BPC-157 + TB-500 Research Use Only